ReviewAbdominal radiology (New York)2020
Dual-energy CT in diffuse liver disease: is there a role?
Review in Abdominal radiology (New York), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Predictive value of dual-energy CT assessment of extracellular volume fraction on efficacy of immune checkpoint inhibitors in patients with liver cancer.Frontiers in oncology · 2025Article
- Ionizing radiation resilience: how metabolically active lichens endure exposure to the simulated Mars atmosphere.IMA fungus · 2025Article
- Photon-counting CT: technical features and clinical impact on abdominal imaging.Abdominal radiology (New York) · 2024Review
- Post-contrast CT liver attenuation alone is superior to the liver-spleen difference for identifying moderate hepatic steatosis.European radiology · 2024Article
- Comparing Different Methods for the Diagnosis of Liver Steatosis: What Are the Best Diagnostic Tools?Diagnostics (Basel, Switzerland) · 2024Article
- What to Expect (and What Not) from Dual-Energy CT Imaging Now and in the Future?Journal of imaging · 2024Review
- Noninvasive diagnosis of liver cirrhosis: qualitative and quantitative imaging biomarkers.Abdominal radiology (New York) · 2024Review
- Spectral CT: Current Liver Applications.Diagnostics (Basel, Switzerland) · 2023Review
- Iodine maps derived from sparse-view kV-switching dual-energy CT equipped with a deep learning reconstruction for diagnosis of hepatocellular carcinoma.Scientific reports · 2023Article
- The Role of Dual-Energy CT for the Assessment of Liver Metastasis Response to Treatment: Above the RECIST 1.1 Criteria.Journal of clinical medicine · 2023Article
- Dual-energy CT: minimal essentials for radiologists.Japanese journal of radiology · 2022Review
- Dual-Energy Computed Tomography Imaging in Early-Stage Hepatocellular Carcinoma: A Preliminary Study.Contrast media & molecular imaging · 2022Article
- The correlation between hepatic fat fraction evaluated by dual-energy computed tomography and high-risk coronary plaques in patients with non-alcoholic fatty liver disease.Japanese journal of radiology · 2021Article
- Advanced CT techniques for assessing hepatocellular carcinoma.La Radiologia medica · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dual-energy CT (DECT) can be defined as the use of two different energy levels to identify and quantify material composition. Since its inception, DECT has benefited from remarkable improvements in hardware and clinical applications. DECT enables accurate identification and quantification of multiple materials, including fat, iron, and iodine. As a consequence, multiple studies have investigated the potential role of DECT in the assessment of diffuse liver diseases. While this role is evolving, this article aims to review the most relevant literature on use of DECT for assessment of diffuse liver diseases. Moreover, the basic concepts on DECT techniques, types of image reconstruction, and DECT-dedicated software will be described, focusing on the areas that are most relevant for the evaluation of diffuse liver diseases. Also, we will review the evidence of added value of DECT in detection and assessment of hepatocellular carcinoma which is a known risk in patients with diffuse liver disease.
Indexed as
Identifiers
32772121What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.